Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/15/2005CA2217515C Pharmaceutical composition containing proton pump inhibitors
03/15/2005CA2191769C Dialysis fluid containing peptides obtained from casein as osmotic agents and bicarbonate ions as buffering agents
03/15/2005CA2149826C 7-glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient
03/15/2005CA2124964C Cdw52-specific antibody for treatment of multiple sclerosis
03/15/2005CA2121678C Vitamin d amide derivatives
03/15/2005CA2086914C Quinolone-and naphthyridone-carboxylic acid derivatives
03/15/2005CA2085785C The use of 4-aminopyridine in the treatment of a neurological condition
03/15/2005CA2063671C Aminoguanidines
03/15/2005CA2054325C Antisense oligonucleotides for treatment of cancer
03/11/2005WO2005103048A1 Quinolone carboxylic acid derivatives, thereof preparation and usage
03/10/2005WO2005022118A2 Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
03/10/2005WO2005022116A2 Antioxodant sensor, methods and compositions
03/10/2005WO2005021750A1 Treatment of menorrhagia, dysmenorrhoea or endometriosis
03/10/2005WO2005021739A1 ANTIBODY AGAINST Nox1 POLYPEPTIDE, METHOD OF DIAGNOSING CANCER WITH THE USE OF Nox1 GENE AND METHOD OF SCREENING CANCER GROWTH INHIBITOR
03/10/2005WO2005021722A2 METHODS AND COMPOSITIONS FOR INHIBITION OF NUCLEAR FACTOR κB
03/10/2005WO2005021721A2 Carboxylesterase inhibitors
03/10/2005WO2005021708A2 Bisphosphonates for prophylaxis and therapy against bioterrorism agents
03/10/2005WO2005021706A2 Delivery of compounds with rehydrated blood cells
03/10/2005WO2005021626A2 Antimicrobial acrylic polymer
03/10/2005WO2005021596A2 Compositions and methods for glycogen synthesis
03/10/2005WO2005021584A2 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
03/10/2005WO2005021573A1 Δ15-d-homosteroids having an androgenic effect
03/10/2005WO2005021559A2 Oxazaborolidines as bacteria effectors
03/10/2005WO2005021555A1 Bicyclic piperazine compound and use thereof
03/10/2005WO2005021552A1 Pyrimidothiophene compounds
03/10/2005WO2005021548A2 Substituted 8-heteroaryl xanthines
03/10/2005WO2005021544A2 N3-substituted imidazopyridine-derivatives as c-kit inhibitors
03/10/2005WO2005021541A2 Process for the production of polymorphs of rosiglitazone maleate
03/10/2005WO2005021540A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
03/10/2005WO2005021539A1 Benzimidazolone compounds having 5-ht4 receptor agonistic activity
03/10/2005WO2005021534A1 1,3-dihydro-2h-indol-2-one derivative
03/10/2005WO2005021529A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
03/10/2005WO2005021523A1 Piperazine substituted compounds used as calcium channel blockers
03/10/2005WO2005021518A1 Condensed ring compound and use thereof
03/10/2005WO2005021515A2 Inhibitors of phosphodiesterase type-iv
03/10/2005WO2005021512A1 Quinoxaline derivatives as neutrophil elastase inhibitors and their use
03/10/2005WO2005021511A1 A novel process for amorphous rosuvastatin calcium
03/10/2005WO2005021504A2 New crystalline forms of carvedilol
03/10/2005WO2005021501A1 Minimally invasive physiological function monitoring agents
03/10/2005WO2005021499A1 N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
03/10/2005WO2005021496A2 Synthesis of derivatives of ginkgolide c
03/10/2005WO2005021495A2 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
03/10/2005WO2005021481A1 N, n’-dibenzyl ethylenediamine salt pf 2-(alpha-hidroxypentyl) benzoic acid and its preparing process and usage
03/10/2005WO2005021095A2 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
03/10/2005WO2005021045A1 Gene therapy for skin diseases using needle free syringe
03/10/2005WO2005021041A1 Intranasal formulations of meloxicam
03/10/2005WO2005021040A2 Compositions useful for treating gastrointestinal motility disorders
03/10/2005WO2005021039A1 Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
03/10/2005WO2005021038A2 Agent for treating metabolic syndrome
03/10/2005WO2005021037A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005WO2005021025A2 MODULATION OF β-CATENIN/TCF ACTIVATED TRANSCRIPTION
03/10/2005WO2005021024A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
03/10/2005WO2005021015A1 Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilisation of glycemia
03/10/2005WO2005021013A1 β-HYDROXY SHORT TO MEDIUM CHAIN FATTY ACID POLYMER
03/10/2005WO2005021012A1 Drug carrier having gemcitabine enclosed therein
03/10/2005WO2005021011A1 Use of surfactant preparations for the treatment of surgical adhesions
03/10/2005WO2005021010A1 Use of bisphosphonates for otosclerosis
03/10/2005WO2005021009A2 Formulations and methods of treating inflammatory bowel disease
03/10/2005WO2005021008A1 Iontophoresis-administered composition
03/10/2005WO2005021007A1 Prevention and treatment of viral hepatitis c
03/10/2005WO2005021006A1 Method and substance for facilitating weaning, reducing morbidity and reducing mortality in cardiac surgeries involving extra-corporal circulation
03/10/2005WO2005021005A2 Process for the preparation of 1,4-benzodiazepine derivatives
03/10/2005WO2005021004A1 Method for preventing or treating an optic neuropathy
03/10/2005WO2005021003A2 Immunosuppressive effects of pteridine derivatives
03/10/2005WO2005021002A1 Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer
03/10/2005WO2005021001A1 Combinations of a pyrimidine containing nnrti with rt inhibitors
03/10/2005WO2005021000A1 Solid oral dosage forms of gatifloxacin
03/10/2005WO2005020999A1 Aryloxy and arylalkyleneoxy substituted imidazoquinolines
03/10/2005WO2005020998A1 Pharmaceutical compositions of moxifloxacin and processes for their preparation
03/10/2005WO2005020997A1 Compositions for veterinary and medical applications
03/10/2005WO2005020996A1 Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
03/10/2005WO2005020995A1 Methods related to the treatment of mucosal associated conditions
03/10/2005WO2005020994A1 Solid dispersions comprising tacrolimus
03/10/2005WO2005020993A1 Modified release compositions comprising tacrolimus
03/10/2005WO2005020992A1 Novel medical use of selective cb1-receptor antagonists
03/10/2005WO2005020990A1 Antibiotic thiazolidines
03/10/2005WO2005020989A1 Cancer treatment with epothilones
03/10/2005WO2005020988A1 Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
03/10/2005WO2005020984A2 Method of reducing the risk of oxidative stress
03/10/2005WO2005020983A2 Combination therapy for glycaemic control
03/10/2005WO2005020982A2 Using selective antagonists of persistent sodium current to treat neurological disorders and pain
03/10/2005WO2005020981A1 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
03/10/2005WO2005020980A1 Acid containing oxaliplatin formulations
03/10/2005WO2005020979A1 A process for the preparation of pharmaceutical compositions of nateglinide
03/10/2005WO2005020978A1 Sustained release oral tablets of gabapentin and process for their preparation
03/10/2005WO2005020977A1 Alpha-ketoglutarate potentiators of insulin secretion
03/10/2005WO2005020976A2 Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
03/10/2005WO2005020975A2 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
03/10/2005WO2005020974A1 Novel use of a polyamine-poor composition for the production of a medical human food
03/10/2005WO2005020973A2 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
03/10/2005WO2005020972A2 Combination therapy for the treatment of ocular neovascular disorders
03/10/2005WO2005020971A1 Use of an angiotensin ii antagonist for the prevention of myocardial infarction
03/10/2005WO2005020970A2 Protease inhibitor compositions for prevention and treatment of skin conditions
03/10/2005WO2005020969A2 A method of treating fibrosis
03/10/2005WO2005020968A2 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
03/10/2005WO2005020967A1 Electric drug transport preparation
03/10/2005WO2005020966A1 Transdermal formulation comprising an opioid analgesic and an aloe composition
03/10/2005WO2005020965A2 Skeletally targeted nanoparticles
03/10/2005WO2005020962A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005WO2005020961A1 Pharmaceutical composition comprising anticonvulsant with taste mask coating
1 ... 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 ... 7860